Premium
Tumour‐associated monoclonal antibodies for the diagnosis and assessment of ovarian cancer
Author(s) -
SHEPHERD JOHN H.,
GRANOWSKA M.,
BRITTON K. E.,
MATHER S.,
SLEVTN MAURICE,
EPENETOS A. A.,
WARD E.G.
Publication year - 1987
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1987.tb02344.x
Subject(s) - exploratory laparotomy , ovarian cancer , immunoperoxidase , monoclonal antibody , medicine , laparotomy , cancer , pathology , antibody , surgery , immunology
Summary. A tumour‐associated radiolabelled monoclonal antibody (HMFG 2) was used to investigate 51 patients who were referred with a pelvic mass and suspected ovarian cancer or recurrent disease. The day before operation the 123 I‐labelled antibody was injected and the patients then underwent radioimmunoscintigraphy immediately and again 4 and 22 h after the injection. An exploratory laparotomy with appropriate surgery was then performed and the tumours were staged. Tumours were positively imaged 3 min‐22 h after injection in all the patients with ovarian cancer, with a mean 0.6% of the injected antibody taken up by the tumour. The presence of HMFG antigen on the tumour was confirmed by immunoperoxidase staining of the surgically‐removed tissues. Of the 51 patients, 39 proved to have ovarian cancer. The accuracy of diagnosis and detection of primary and metastatic malignant disease was 95% when correlating pre‐operative radioimmune scan findings and laparotomy findings. The procedure is minimally invasive, apparently without side‐effects and offers information for tumour detection as an adjunct or alternative to existing methods.